16:38
Cryosurgery Instead of Radiation Therapy after Lumpectomy
V. Suzanne Klimberg
In eight-year data on small, favorable tumors, endocrine therapy alone left a 16 percent recurrence rate, radiation alone 9 percent, and the two together about 3 percent. Survival was the sa...
In eight-year data on small, favorable tumors, endocrine therapy alone left a 16 percent recurrence rate, radiation alone 9 percent, and the two together about 3 percent. Survival was the same in all three groups. Dr. Suzanne Klimberg opened there to make the uncomfortable point plainly: most women with favorable breast cancers gain little from whole breast radiation, and we still give it to nearly all of them.
Her talk asks whether we can finish local treatment in the operating room instead. Klimberg walks through the trials that already point toward de-escalation, then presents her own alternative to radiation: intraoperative cavitary radiofrequency ablation, done at the time of lumpectomy. She lays out the preclinical work, the single-institution ABLATE-1 experience, a published seven-site phase 2 trial in 242 patients, and a new surgeon-friendly device now heading into an Alliance Cooperative Group trial. The through-line is a practical one for anyone who treats early breast cancer: match the intensity of local therapy to the small group who truly need it, and spare the rest the cost, the toxicity, and the trips they often cannot make.
Key points for clinicians:
In small favorable tumors, radiation lowers local recurrence but not survival, so the clinical question is not whether it works but how to identify the few patients who benefit. Trials like the Canadian and PRIME data show good local control in selected older women, and IDEA-type work found roughly 100 percent breast cancer survival with endocrine therapy alone at recurrence scores under 18. The DEBRA trial (NRG-BR007) is now randomizing endocrine therapy plus radiation against endocrine therapy alone in HER2-negative tumors stratified by oncotype under 11 and 11 to 18.
Radiation carries real access and toxicity costs. Klimberg notes that fewer than 80 percent of patients in parts of the rural United States complete their full prescribed dose, and that some women choose mastectomy simply because they cannot return daily for treatment.
The proposed alternative is intraoperative radiofrequency ablation of the lumpectomy cavity, producing about a one centimeter concentric ablation zone, validated on mastectomy and resection specimens and monitored in real time with Doppler. It adds roughly 15 to 20 minutes and can ablate residual disease at focally positive margins, reducing the need to return for re-excision.
In ABLATE-1 (100 patients, single institution), two thirds of patients with positive margins avoided re-excision and two thirds of the full cohort avoided radiation entirely, with low complications, less pain, and good cosmesis.
In the published seven-site phase 2 trial (242 patients, risk-adjusted so node-positive and aggressive disease still received whole breast radiation), the mastectomy rate was 2.8 percent, re-excision for positive margins under 5 percent, and local recurrence 2.6 percent. About 80 percent of patients avoided radiation. Breast pain at 6 to 12 months was 19 percent in the irradiated group versus 1.7 percent with ablation alone, roughly fivefold less, with good to excellent cosmesis in almost 90 percent.
A new device that plugs into the existing Bovie unit makes the technique faster to learn and available even in rural operating rooms. A first report covered 55 ablations in 44 women, and the FDA has asked for a small additional cohort before the Alliance trial.